Curative therapy after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: A Multinational Retrospective Study
See if people with unresectable hepatocellular carcinoma who respond to atezolizumab plus bevacizumab and then receive curative therapy do as well or better than those who get a complete response to the drugs alone or remain in partial response without curative treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1600 (estimated) |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Drugs / interventions | tiragolumab, relatlimab, tocilizumab, chemotherapy, atezolizumab, bevacizumab, immunotherapy |
| Locations | 1 site (Taipei, Select) |
| Trial ID | NCT07091942 on ClinicalTrials.gov |
What this trial studies
This is a multinational, multicenter retrospective chart-review of patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab as first-line systemic therapy and achieved a complete or partial response by RECIST v1.1. The study will identify patients who went on to receive curative treatments after response and compare their subsequent outcomes to patients with drug-alone complete responses and those who remained in partial response without curative therapy. Eligible patients may have had macrovascular invasion or extrahepatic spread prior to Atezo-Bev, while cases of fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma and those who received concurrent anti-CTLA4 or simultaneous locoregional therapy are excluded. The primary aim is to clarify differences in disease-free and overall outcomes across these real-world cohorts to inform treatment sequencing decisions.
Who should consider this trial
Good fit: Patients with histologically or clinically diagnosed hepatocellular carcinoma who received atezolizumab plus bevacizumab as first-line systemic therapy and achieved a complete or partial response by RECIST v1.1 are the intended cohort.
Not a fit: Patients with fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma, those who received anti-CTLA4 antibodies concurrently, or those who did not receive Atezo-Bev as first-line therapy would not be eligible and therefore would not benefit from this study's findings.
Why it matters
Potential benefit: If successful, the findings could clarify whether adding curative therapy after response to atezolizumab plus bevacizumab improves long-term disease-free survival and help guide treatment decisions.
How similar studies have performed: Some case series and small cohort reports have described successful conversion to curative therapy after systemic immunotherapy, but large multicenter comparative data are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically or clinically (the presence of liver cirrhosis and typical HCC imaging findings by multi-phase CT or MRI) diagnosed HCC. 2. Received Atezo-Bev containing treatment as first-line systemic therapy for HCC 3. Patients with or without macrovascular invasion and main portal vein invasion before Atezo-Bev containing treatment can be enrolled 4. Patients with or without extrahepatic spread before Atezo-Bev containing treatment can be enrolled 5. Obtained CR or PR, according to RECIST version 1.1, to Atezo-Bev treatment Exclusion Criteria: 1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma. 2. Received anti-CTLA4 antibodies simultaneously with Atezo-Bev Patients who received Atezo-Bev in combination with investigational drugs such as tiragolumab, relatlimab, and tocilizumab were allowed to enter the study. 3. Received locoregional therapy simultaneously with Atezo-Bev treatment, such as transarterial chemoembolization (TACE), hepatic arterial infusion of chemotherapy (HAIC), transarterial radioembolization, radiofrequency ablation, and microwave ablation before obtaining PR or not for curative intent
Where this trial is running
Taipei, Select
- National Taiwan University Hospital — Taipei, Select, Taiwan (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.